SPX4,076.57-3.54 -0.09%
DIA344.41-1.74 -0.50%
IXIC11,482.45+14.45 0.13%

B. Riley Securities Downgrades Spectrum Pharmaceuticals to Neutral, Lowers Price Target to $1

Benzinga · 11/16/2022 08:19
B. Riley Securities analyst Mayank Mamtani downgrades Spectrum Pharmaceuticals (NASDAQ:SPPI) from Buy to Neutral and lowers the price target from $1.5 to $1.